news
EC grants Marketing Authorisation for dinutuximab
17 August 2015 | By Victoria White
The EC has granted Marketing Authorisation for dinutuximab for the treatment of high-risk neuroblastoma in patients aged 12 months to 17 years...
List view / Grid view
European Commission (EC)
news
EC grants Orphan Drug Designation to SGX301
4 August 2015 | By Victoria White
The EC has granted orphan drug designation to Solgenix’s synthetic hypericin (the active ingredient in SGX301) for the treatment of cutaneous T-cell lymphoma...
news
EC approves Keytruda for the treatment of melanoma
23 July 2015 | By Victoria White
The EC has approved Merck’s Keytruda (pembrolizumab) for the treatment of advanced (unresectable or metastatic) melanoma in adults...
news
Janssen’s ibrutinib approved by the EC for the treatment of Waldenström’s macroglobulinemia
10 July 2015 | By Victoria White
Janssen-Cilag International announced today that the European Commission (EC) has approved Imbruvica® (ibrutinib) capsules as a treatment option for adult patients with Waldenström’s macroglobulinemia (WM).
news
European Commission approves Orfadin oral suspension
29 June 2015 | By Victoria White
The European Commission (EC) has approved the oral suspension formulation of Sobi’s Orfadin for the treatment of Hereditary Tyrosinaemia type-1 (HT-1)...
news
EC approves Opdivo for the treatment of advanced melanoma patients
22 June 2015 | By Victoria White
The European Commission has approved Bristol-Myers Squibb’s Opdivo, a PD-1 immune checkpoint inhibitor, for the treatment of advanced melanoma in adults...
news
UMC Utrecht’s new liver cancer treatment approved for use in Europe
14 April 2015 | By Victoria White
A new liver cancer treatment developed by the UMC Utrecht that uses uses radioactive holmium microspheres has received the European CE mark...
news
MODHEP film debuts at European Parliament
1 April 2015 | By Victoria White
"MODHEP: Understanding liver cancer" shown at European Parliament to delegates at an event celebrating collaboration between the EU and other countries...
news
Saxenda approved in Europe for the treatment of obesity
24 March 2015 | By Victoria White
Novo Nordisk has announced that the European Commission has granted marketing authorisation for Saxenda ® (liraglutide 3 mg) for the treatment of obesity...
news
European Commission approves additional indication for VELCADE® (bortezomib) in mantle cell lymphoma
6 February 2015 | By Janssen EMEA
Janssen-Cilag International NV (Janssen) announced today that the European Commission has approved a variation to the terms of the marketing authorisation of VELCADE® (bortezomib) in combination with rituximab, cyclophosphamide, doxorubicin and prednisone for the treatment of adult patients with previously untreated mantle cell lymphoma (MCL) who are unsuitable for blood…
news
Once daily treatment option made available for up to one million adult Britons with type 2 diabetes and moderate chronic kidney disease
21 January 2015 | By Aurora
A once daily injection has been approved for adults with type 2 diabetes and moderate renal impairment (stage 3 chronic kidney disease) in the UK...
news
OFEV® (nintedanib*) approved in the EU for the treatment of IPF
19 January 2015 | By Boehringer Ingelheim
Boehringer Ingelheim today announced that the European Commission (EC) has approved nintedanib* for the treatment of idiopathic pulmonary fibrosis (IPF), following an expedited review and positive CHMP opinion on 20 November 2014. Nintedanib* will be marketed in the EU under the brand name OFEV®...
news
Action required to tackle EU alcohol consumption
27 November 2014 | By European Alcohol Policy Alliance
Today over 300 representatives from Health Ministries, the European Institutions, public health experts and concerned stakeholders have gathered in Brussels to call on the European Commission President Jean-Claude Juncker and his team to take actions to prevent and reduce the burden of alcohol on European societies...
news
European Commission grants marketing authorization for Gilead’s Zydelig® (Idelalisib) for the treatment of chronic lymphocytic leukemia and follicular lymphoma
22 September 2014 | By Gilead Sciences
Gilead Sciences, Inc. announced that the European Commission has granted marketing authorization for Zydelig® (idelalisib), 150 mg tablets, a first-in-class oral treatment for two incurable blood cancers - chronic lymphocytic leukemia and follicular lymphoma...
news
European Commission grants Lilly and Boehringer Ingelheim’s insulin glargine product marketing authorisation in Europe
10 September 2014 | By Boehringer Ingelheim
The European Commission granted marketing authorisation for Eli Lilly and Company and Boehringer Ingelheim’s insulin glargine product, indicated to treat diabetes in adults, adolescents and children aged 2 years and above...
